March 23, 2010 – The FDA granted approval for diltiazem hydrochloride extended-release tablets to treat hypertension, which is the generic equivalent to Biovail Laboratories International SRL's Cardizem LA product.
Watson Pharmaceuticals Inc. will produce the generic drug and plans for its immediate release. For the 12-months ending Dec. 31, 2009, Cardizem LA had total U.S. sales of approximately $94.1 million, according to IMS Health.
For more information: www.watson.com
July 16, 2026 — Merck has received U.S. Food and Drug Administration (FDA) approval for Lipfendra (enlicitide) tablets ...
July 16, 2026 
Jan. 27, 2026 — Cytokinetics, Inc. has announced that Myqorzo (aficamten) is now available for prescription in 5 mg, 10 ...
January 28, 2026 
Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were ...
November 19, 2025 
Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each ...
September 25, 2025 
Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...
September 23, 2025 